AIM IMMUNOTECH INC (AIM)
US00901B1052 - Common Stock
Taking everything into account, AIM scores 2 out of 10 in our fundamental rating. AIM was compared to 565 industry peers in the Biotechnology industry. AIM may be in some trouble as it scores bad on both profitability and health. AIM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AIM has reported negative net income.
AIM had a negative operating cash flow in the past year.
In the past 5 years AIM always reported negative net income.
In the past 5 years AIM always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -178.46%, AIM is not doing good in the industry: 88.95% of the companies in the same industry are doing better.
AIM's Return On Equity of -459.60% is on the low side compared to the rest of the industry. AIM is outperformed by 79.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -178.46% | ||
| ROE | -459.6% | ||
| ROIC | N/A |
ROA(3y)-76.87%
ROA(5y)-59.64%
ROE(3y)-122.39%
ROE(5y)-92.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of AIM (71.14%) is better than 83.42% of its industry peers.
The Profit Margin and Operating Margin are not available for AIM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AIM has been increased compared to 1 year ago.
Compared to 5 years ago, AIM has more shares outstanding
AIM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
AIM has an Altman-Z score of -42.87. This is a bad value and indicates that AIM is not financially healthy and even has some risk of bankruptcy.
AIM has a worse Altman-Z score (-42.87) than 93.05% of its industry peers.
AIM has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
AIM's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. AIM is outperformed by 60.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -42.87 |
ROIC/WACCN/A
WACC10.4%
2.3 Liquidity
A Current Ratio of 1.17 indicates that AIM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.17, AIM is doing worse than 84.67% of the companies in the same industry.
AIM has a Quick Ratio of 1.17. This is a normal value and indicates that AIM is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AIM (1.17) is worse than 83.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
AIM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.00%.
AIM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.64%.
AIM shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.26% yearly.
EPS 1Y (TTM)-45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)19.64%
Revenue growth 3Y7.41%
Revenue growth 5Y-11.26%
Sales Q2Q%19.05%
3.2 Future
The Earnings Per Share is expected to grow by 11.16% on average over the next years. This is quite good.
AIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 217.99% yearly.
EPS Next Y43.33%
EPS Next 2Y14.45%
EPS Next 3Y7.26%
EPS Next 5Y11.16%
Revenue Next Year-4.46%
Revenue Next 2Y236.73%
Revenue Next 3Y189.77%
Revenue Next 5Y217.99%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AIM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.45%
EPS Next 3Y7.26%
5. Dividend
5.1 Amount
No dividends for AIM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AIM IMMUNOTECH INC
NYSEARCA:AIM (11/21/2024, 2:18:02 PM)
0.2131
+0.01 (+6.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -178.46% | ||
| ROE | -459.6% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.14% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-45%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y43.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.64%
Revenue growth 3Y7.41%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y